key: cord-0822678-6iuqv71f
authors: McGonagle, Dennis; O'Donnell, James S; Sharif, Kassem; Emery, Paul; Bridgewood, Charles
title: Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
date: 2020-05-07
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(20)30121-1
sha: 284c21d6e303599fe8a70a4703c9b1a01241c066
doc_id: 822678
cord_uid: 6iuqv71f

The lung pathology seen in patients with coronavirus disease 2019 (COVID-19) shows marked microvascular thrombosis and haemorrhage linked to extensive alveolar and interstitial inflammation that shares features with macrophage activation syndrome (MAS). We have termed the lung-restricted vascular immunopathology associated with COVID-19 as diffuse pulmonary intravascular coagulopathy, which in its early stages is distinct from disseminated intravascular coagulation. Increased circulating D-dimer concentrations (reflecting pulmonary vascular bed thrombosis with fibrinolysis) and elevated cardiac enzyme concentrations (reflecting emergent ventricular stress induced by pulmonary hypertension) in the face of normal fibrinogen and platelet levels are key early features of severe pulmonary intravascular coagulopathy related to COVID-19. Extensive immunothrombosis over a wide pulmonary vascular territory without confirmation of COVID-19 viraemia in early disease best explains the adverse impact of male sex, hypertension, obesity, and diabetes on the prognosis of patients with COVID-19. The immune mechanism underlying diffuse alveolar and pulmonary interstitial inflammation in COVID-19 involves a MAS-like state that triggers extensive immunothrombosis, which might unmask subclinical cardiovascular disease and is distinct from the MAS and disseminated intravascular coagulation that is more familiar to rheumatologists.

The coronavirus disease 2019 (COVID-19) pan demic and earlier coronavirus outbreaks have been associated with adult respiratory distress syndrome (ARDS) and worse outcomes in older patients. 1,2 The severity of systemic inflammation in response to human coronavirus family members has features reminiscent of a cytokine storm or macrophage activation synd rome (MAS), also known as secondary haemophagocytic lympho histocytosis (sHLH). 3, 4 This response has inspired use of directed anticytokine therapies for severe COVID-19 pneumonia, as these agents are known to be useful in diseases on the MAS spectrum. 4, 5 A key feature of sHLH or MAS is haemophagocytosis and an acute consump tive coagulopathy, leading to disseminated intravascular coagu lation. Disseminated intravascular coagulation has also been reported in COVID-19 pneumonia, but usually as a pre-terminal event. 6, 7 The hypercytokinaemia with extreme hyper ferritinaemia that is typically seen with sHLH is also evident in some patients with COVID-19 pneumonia. 4

MAS-like pulmonary immunopathology characteristic of COVID-19 pneumonia is distinct from classical sHLH. 8 Haemphagocytosis is a cardinal feature of MAS 9,10 and has been reported in patients with severe acute respiratory syndrome (SARS). 11, 12 In SARS, this process might involve phagocytosis of extravascular red blood cells consequent to severe lung microvascular damage, microhaemorrhage with physiological haemophagocytosis of extravascular red blood cells, or possibly very advanced disease with frank MAS-like pathology and disseminated intravascular coagula tion (figure 1). The hypercytokinaemia characteristic of sHLH or MAS is often associated with extremely high serum ferritin concentrations (≥10 000-100 000 ng/mL), whereas in patients with COVID-19, serum ferritin concentrations are typically in the 500-3000 ng/mL range, at least early in the disease course. Another clear distinguishing feature of sHLH or MAS is liver function derangement, which can contribute to coagulopathy secondary to loss of liver synthetic function and is not typically seen in patients with COVID-19 (figure 1).

Extensive lung infiltration by macrophages and other immune cells leading to diffuse alveolar damage has been reported in SARS pneumonia, with similar findings emerging in patients with COVID-19 pneumonia. 12, [14] [15] [16] The extensive nature of viral infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in diffuse lung inflammation that involves the large juxtaposed pulmonary vascular network. 8 The diffuse, slowly evolving COVID-19 pneumonia has similarities to a MASlike syndrome with regard to both clinical and laboratory features. These clinical findings suggest that an initial pulmonary intravascular coagulopathy occurs in patients with COVID-19 pneumonia that is distinct from dissemina ted intravascular coagulation. 8 Herein, we propose a model for the pathophysiology of this pulmonary intravascular coagulopathy and describe how extensive coronavirus infection and age-related changes in immunity, com bined with diffuse pulmonary immuno thrombosis, explain the cardiovascular mortality in these patients (table 1) .

Acute respiratory infections are associated with a high risk of cardiovascular-related death, especially in the weeks immediately after infection, and particularly in older patients and those with pre-existing cardiovascular disease. Severity of pneumonia in these patients is linked to an increased risk of death. 17, 18 Of particular note, one pathology study showed similar vascular changes in postmortem tissue from patients with bronchopneumonia not related to SARS as was found in individuals who died from Viewpoint SARS, 20 indicating that vascular thrombosis triggered by infection, rather than the infection itself, could be key (figure 2).

Coronavirus family members show tropism for angiotensin-converting enzyme 2 (ACE2) on type II pneumocytes. This tropism, along with the close anatomical juxtaposition of type II pneumocytes and the pulmonary vascular network, and a severe multifaceted inflammatory reaction, is likely to drive the generalised pulmonary hypercoagulable state seen in patients with COVID-19 (figure 2). 8, 21 Single-cell sequencing analysis has recently shown that most pulmonary gene expression is confined to a small population of type II pneumocytes, and ACE2 is largely absent from endothelial cells and alveolar macrophages. 22 From a clinical perspective, the diffuse alveolar changes (determined by CT scan) seen in patients with COVID-19 are distinct from bronchopneumonia and show how SARS-CoV-2 interfaces with a large area of the pulmonary microvasculature. This finding probably explains the propensity for diffuse pathology in patients with COVID-19 pneumonia. In these patients, extensive air space changes on CT are associated with a worse prog nosis compared with patients not showing these changes. 23 Diffuse disease on CT is also a feature of patients who died from SARS-CoV infection (figure 2). 23 ACE2 has been shown to regulate innate immunity, and mice with a genetic deletion of ACE2 developed more severe pulmonary inflammation after acid inhalation than did wild-type mice. 24 These findings suggest that ACE2 downregulation could aggravate inflammation over a wide alveolar capillary network. It was subsequently shown that injecting the SARS spike protein led to similar lung pathology in mice, probably due to internalisa tion of the ACE2 receptor and subsequent inhibi tion of ACE2-mediated generation of the imm unoregulatory angiotensin (1-7) peptide, which sig nals via the MAS1 receptor. 24 Mice lacking ACE2 also developed more severe pneumonitis and had higher mortality after influenza infection compared with wild-type mice. 25 Theoretically, a similar mech anism could increase the proclivity towards immuno thrombosis in humans. In humans, the Middle East res piratory syn drome coronavirus (MERS-CoV) principally uses the dipeptidyl peptidase 4 (DPP4) receptor, which is not restricted to type II pneumocytes; nonetheless, this virus results in clinical features and pathology similar to SARS-CoV and SARS-CoV-2, including a high mortality rate. 26 Analogous to ACE2, in some experimental systems the DPP4 receptor might negatively regulate lymphocyte function, which could indicate a shared coronavirus-specific mechanism that contributes to pulmonary intra vascular coagulopathy (panel). 27

The SARS-CoV-2 and SARS-CoV virus genomes are highly homologous, and patients infected with these viruses appear to share common clinical and pathological features. 28, 29 Initial post-mortem reports from three patients with SARS indicated not only diffuse alveolar damage and small pulmonary vessel thrombosis and haemorrhage, but also a more generalised small vessel thrombosis. 30 A second post-mortem study of six patients (A) Secondary haemophagocytic lymphohistiocytosis or macrophage activation syndrome is associated with organomegaly, thrombocytopenia, haemophagocytosis, and disseminated intravascular coagulation with pulmonary involvement in half of cases. 13 Activation of bone marrow, lymphoid organ, hepatic Kupffer cells, and circulating mononuclear cells lead to a severe consumptive coagulopathy with low fibrinongen levels and increased fibrinogen degradation. Additionally, liver dysfunction exacerbates the consumptive coagulopathy. A rapid onset disseminated intravascular coagulation pattern with hyperferritinaemia reflects generalised haemophagocytosis with erythrocyte degradation, sequestration, and export with diffuse clotting and bleeding. (B) Pulmonary involvement without generalised lymphoid organ hyperplasia is typical of COVID-19 pneumonia. Haemophagocytosis, albeit intrapulmonary, has also been reported in coronavirus family infection. 12 However, in the early stages systemic coagulopathy is not a feature. Such intrapulmonary haemophagocytosis, which then drains to regional nodes, indicates removal of extravascular red blood cells mediated by activated macrophages, secondary to vascular injury. A disseminated intravascular coagulation picture might also develop late in the course of COVID-19 pneumonia in patients who develop acute respiratory distress syndrome. COVID-19=coronavirus disease 2019. 

reported vascular pathology in two cases. 12 A study of pathological specimens from 20 patients with SARS showed the presence of not only diffuse alveolar damage, but also fibrin thrombi, small vessel occlusion, and pulmonary infarction in upwards of 80% of cases. 19 A review of aggregated SARS pathology reports showed evidence for vessel wall oedema, inflam matory cell infiltra tion into the walls of the pulmonary microvasculature, marked haemorrhagic necrosis, and vessel microthrombi mostly confined to the lung and pulmonary tissue infarction, in the context of septal inflammation and diffuse alveolar damage. 31 Some data have emerged from patients with COVID-19 pneu monia that show a similar pulmonary vascular picture with blood vessel wall oedema, modest vessel wall immune cell infiltra tion, hyaline thrombosis, haemor rhagic change, and infarction. 15, 32, 33 Emergent data have also emphasised prom inent capillary thrombosis, 33 and one study reported cardiomegaly and right ventricular dilatation, pointing toward the expected development of pulmonary artery hypertension. 33

Myocarditis might occur after severe respiratory viral pneumonia. Although this outcome is relatively rare, it is well documented, especially in younger women following influenza infection (table 2) . Understandably, increased cardiac enzymes in patients with COVID-19 has been taken to potentially represent myocarditis or cardiac vasculitis associated with viral infection. In SARS-CoV infection, however, most evidence points away from cardiac involvement. 40, 41 The ACE2 receptor is expressed on endothelial cells, and one in situ hybridisation study suggested that pulmonary endothelial cells are infected with SARS-CoV. 42 Other studies showed a complete absence or very low level of potential endothelial cell infection. 40, 41 Furthermore, a study in patients with SARS suggested a close link between infection of pneumocytes and inflammatory cytokine expression in the same cells; 43 however, this link was not reported for endothelium. In SARS-CoV-2 infection, publications have reported that viral RNA was undetectable in the blood 36 A role for the ACE2 receptor in cardiovascular biology predates the link between pulmonary pathology and COVID-19 pneumonia. Genetic deletion of ACE2 in rodents was associated with ventricular contractility defects, but there was no evidence of cardiomyopathy or fibrosis. 45 The link between ACE2 downregulation in lung tissue (either in genetically manipulated mice or mice treated with SARS spike protein) and increased inflammation suggests a relatively simple model, in which coronavirus infection of ACE2-expressing cardiomyocytes or cardiac endothelium might trigger a similar inflammatory pathology. In the most comprehensive study of cardiac involvement in patients who died from SARS, viral RNA was detectable in a third of post-mortem cardiac tissues and was associated with both decreased ACE2 expression and increased macrophage infiltration. 37 The same study showed no evidence of myocyte necrosis or lymphocytic infiltration, which are both hallmarks of viral myocarditis. 37, 46 Overall autopsy reports, including those emerging in COVID-19, vary from showing no clinically significant pathology or infiltrating macrophages, and some reports of occasional infiltrating CD4 T cells. 33 The cardiac pathology in COVID-19 pneumonia needs evaluation in view of known cardiovascular comorbidities, including hypertension and pulmonary intravascular coagulopathy, as well as the MAS-like state with associated hypoxaemia and secondary pulmonary artery hypertension. The hypercytokinaemia that is part of the MASlike state could modify ACE2 expression independently of viraemia. One key cytokine characteristic of MAS-like pathology, interferon-γ, has been shown to downregulate ACE2 expression on an epithelial cell line; however, this finding has not been reported for heart cells. 47 Therefore, reported changes in the heart tissue, including endothelium, could represent a cytokine and hypoxia effect rather than direct viral infection.

The key early laboratory observations in patients with COVID-19 pneumonia include elevated plasma D-dimer concentrations in conjunction with elevated cardiac markers, including brain natriuretic peptide, creatine kinase, and troponin T. 48 Elevation of troponin T at hospitalisation is linked to a poor prognosis. 48 Similarly, a 2020 study reported that elevated plasma levels of fibrin degradation products, including D-dimers, constitutes a significant inde pendent biomarker of poor prognosis. 6 For example, Zhou and colleagues 23 reported that 117 (68%) of 172 patients presenting with COVID-19 had increased activation of coagulation, as indicated by elevated D-dimer concentra tions at presentation (>0·5 ug/mL). Importantly, D-dimer concentrations above 1 µg/mL were associated with an 18 times increased odds ratio for fatal outcome. 23 Further more, progressive elevation of D-dimer and fibrin degrada tion products were seen in non-survivors. 23 However, despite this increase in D-dimers, patients with This finding is reflected in the consistent observation that platelet counts and fibrinogen con centration are not substantially reduced in patients with COVID-19, despite marked increases in D-dimer concen trations. 49 Fibrinogen generally remains elevated in these patients, consistent with an ongoing acute phase response.

Severe COVID-19 sepsis is associated with a marked MAStype picture, and increased inflammatory markers and ferritin concentrations that undoubtedly result in local activation of pulmonary vasculature endothelial cells. For example, interleukin (IL)-1, IL-6, and tumor necrosis factor have all been shown to trigger acute endothelial cell activation. 50 Given the crucial roles played by endothelial cells in maintaining normal haemostasis, regulating fibrino lysis, and determining vessel wall permeability, local endothelial cell dysfunction in the pulmonary microvasculature is likely to play an important role in the thrombo inflammatory processes that ultimately result in COVID-19 vasculopathy, ventilation perfusion mismatch, and a clinical phenotype of refractory ARDS. Additionally, the MAS-like picture associated with COVID-19 pneumonia will trigger expression of active tissue factor, both on endothelial cells and on activated infiltrating macrophages and neutrophils. 50 The net effect will be local presentation of blood-borne tissue factor within the lungs, which will further amplify activation of the coagulation cascade. Importantly, endothelial cell disruption, tissue factor expression, and activation of the coagulation cascade will all be progressively exacerbated by development of local hypoxia, 51 establishing a deleterious positive thromboinflammatory feedback loop within the small vessels of the lungs with thrombosis and haemorrhage (figure 3). Beyond the coagulopathic changes occurring within the pulmonary vasculature, a study of bronchoalveolar lavage showed that both severe pneumonia and ARDS are associated with enhanced thrombin gen eration and fibrin deposition within the bronchoalveolar system. 52 These changes correlate with severity of inflam mation 53 and are primarily driven by upregulation of tissue factor expression within the alveoli, coupled with a reduction in fibrinolysis induced by plasminogen activa tion inhibitor 1. 54 The biological mechanisms responsible for the extremely elevated plasma D-dimer concentra tions in patients with severe COVID-19, together with the marked variations observed between individuals, are unclear. Nonetheless, these data clearly suggest hyper active fibrinolysis with increased plasmin generation. Collect ively, these findings have led to the suggestion that elevated plasmin (and plasminogen) concentrations might represent a risk factor for COVID-19 susceptibility. 55 Development of hypoxaemia, secondary to ARDS that is induced by COVID-19, might also activate the coagulation cascade and could be important in endothelial dysfunction beyond the capillary network. 56, 57 Hypoxaemia might also play a role in adjacent small pulmonary vascular thrombosis. 56 Viewpoint immunothrombosis, in containment of bacterial infection and spread is well established, but its role in viral infection is not so well known. 58 Likewise, the role of local pulmonary intravascular immunity and its effects on the phenotype of pulmonary intravascular coagulopathy is completely unknown. 59 Nevertheless, access to the circulation in an artificial adenovirus model system triggers a MAS-like phenomenon with disseminated intravascular coagulation. 60 The role of positive pressure ventilation as a factor driving release of viral nucleic acids and proteins across damaged alveolar endothelial cell barriers is another factor that needs consideration as a potential iatrogenic contributor to immunothrombosis and poor outcomes. Experimental SARS models have shown that normal aged primates have a similar degree of viral replication as younger primates, but that aged primates have more pulmonary damage and lower activation of type 1 interferon responsive gene pathways. 61 At the molecular level, aged primates showed exacerbated innate immune res ponses associated with NF-kB pathway activation, such as elevated IL-8 and expression of tissue factor, which activates the extrinsic clotting pathway protein. 61 It is well established that type 1 interferon responses decrease with age in humans, 62 and also in response to viral infection, but the age at which this transition occurs needs better definition. 63 Viral or age-related impairment in type 1 interferon production appears to be associated with a second wave of inflammatory cytokine production and tissue factor expression that might substantially contribute to pulmonary intravascular coagulopathy. 8

The role of anticoagulation in the setting of COVID-19 pulmonary intravascular coagulopathy is of considerable interest. Expert recommendations for the use of anticoagulants have already been published, reflecting the recogni tion of clotting dysregulation. 64 The potential relevance of anticardiolipin antibodies in the critical care setting of COVID-19 is also recognised, but is of uncertain clinical significance. 65 However, some data are available, mostly derived from prospective cohort studies. In a study of nearly 450 patients with COVID-19, low molecular weight heparin (mostly used in prophylactic doses rather than therapeutic doses) did not confer an overall survival advantage. 49 However, the regimen was associated with improved survival in the group with a high sepsis-induced coagulopathy score and in patients with D-dimer concentrations that were more than six times the upper limit of normal. 49 The role and timing of anticoagulation in this extensive virus-related immuno thrombosis, especially where pulmonary haemorrhaging occurs, needs careful considera tion. In disseminated intravascular coagulation, thrombosis and bleeding might occur simultaneously, and the same scenario also appears to arise in pulmonary intravascular coagulopathy (figure 3).

Given the MAS-like pathology of COVID-19 pneumonia, the question arises whether anticytokine therapy will ameliorate the diffuse immunothrombosis process associated with severe cases. In the translational setting, the use of the IL-1β blocker canakinumab is associated with a decreased risk of all-cause cardiovascular mortality, 66 with an increased benefit in patients with the most dramatic reductions in serum IL-6. 67 Unlike in low grade arterial inflammation in the absence of overt infection, it is still unclear whether severe COVID-19-associated MAS with pulmonary intravascular coagulopathy will be successfully targeted with these strategies; ongoing viral infection might represent a major hurdle in this context. 8 In the past year, it has also emerged that the coagulation and immune systems are directly linked via thrombin cleavage of IL-1α from macrophages and platelets. 68 This novel mechanism is of special interest with regard to anakinra, which blocks both the IL-1α and IL-1β pathways, whereas monoclonal antibodies (eg, canakinumab) selectively block IL-1β. 68 The most crucial question for optimal therapeutic strategies is whether the emergent early activation of coagulopathy and fibrinolysis in patients with COVID-19

Scheme showing how extensive COVID-19 lung involvement with large anatomical interface between infected type II pneumocytes, extensive interstitial immunocyte activation similar to macrophage activation syndrome, and the extensive pulmonary microvascular network, triggers diffuse pulmonary bed extrinsic inflammation with immunothrombosis. This inflammation causes microthrombotic immunopathology that leads to right ventricular stress and contributes to mortality. Diffuse type II pneumocyte centric pathology with extension into the interstitium leads to extensive pulmonary macrophage recruitment and activation, resulting in a clinical picture similar to local macrophage activation syndrome. Proinflammatory and procoagulants gain access to the capillary network (lower circle). The low pressure nature of the vascular system and thin vessel walls in and proximal to the alveolar network triggers immunothrombosis by various mechanisms (eg, local elevations in proinflammatory cytokines), vessel wall tissue damage with tissue factor production, and direct injury to small vessels. Vigorous fibrinolytic activity (detected early by D-dimer elevation) might not keep in check the extensive microthrombi formation, leading to the evolution of pulmonary infarction, haemorrhaging, and pulmonary hypertension induced by pulmonary intravascular coagulopathy, all of which are driven by COVID-19 inflammation. Thus, risk factors for cardiovascular disease might increase the likelihood of death in severe COVID-19 inflammation. COVID-19=coronavirus disease 2019. Viewpoint pneumonia is purely due to an appropriate immune response to the virus, or whether there is a degree of excessive inflammation that could be targeted to help prevent progression of pulmonary intr avascular coagulopathy. The potential survival advantage of drugs pioneered to treat inflammatory and hyper inflammatory states needs to be viewed from the perspective of severe diffuse pulmonary immunothrom bosis. The combination of immunomodulatory and anti coagulant strategies in patients with high D-dimer concentrations and evidence of myocardial stress warrants especially close attention. The use of Janus kinase (JAK) pathway inhibi tion needs careful scrutiny given the association between JAK inhibitors and thromboembolic disease. 69 Some bleeding complications outside of the lung have been described in patients with COVID-19; this response is perhaps unsurprising in the few cases of pulmonary intravascular coagulopathy that progress to systemic disseminated intravascular coagulation. Reports of acute necrotising encephalopathy, which is associated with haemorrhage, are also emerging. 70 However, this rare condition is well recognised in association with viral infections in general. 71 Given that ACE2 is expressed on endothelial cells, the notion of thrombosis outside either pulmonary or disseminated intravascular coagulopathy needs further consideration.

This pulmonary intravascular coagulopathy model has implications for understanding cardiovascular mortality in the COVID-19 pandemic. This model shifts the focus away from COVID-19-related myocarditis or coronary vascular involvement, with cardiac injury secondary to viral infection of myocytes or endothelial cells expressing ACE2, and towards a scenario of multisite pulmonary vascular thrombosis with progressive myo cardial ischaemia. The immunothrombotic pathology that evolves over several days in some patients with COVID-19 pneumonia is likely to manifest in individuals with underlying cardiovascular risk factors such as obesity, hypertension, and type 2 diabetes, and pathology will be compounded by the cardiac ischaemia that accompanies development of ARDS. Cardiovascular mortality is higher in men than in women aged 30-64 years in many different populations. 72 These well known risk factors might also account for racial differences in COVID-19 mortality. 73, 74 The COVID-19 pandemic, characterised by profound immunological changes that constitute a pulmonary MAS-like picture, is revealing a large burden of subclinical cardiovascular disease among patients predisposed to disease, by slowly triggering an extensive pulmonary immunothrombosis. Our model offers a different and robust alternative to the proposed effects of medications on ACE2 expression with resulting increased viral infectivity. 75 It is also important to determine the degree to which COVID-19-mediated diffuse alveolar damage with development of ARDS in the absence of coagulopathy might also contribute to outcomes, because emerging post-mortem reports do not report this pathology in all cases.

Diffuse pulmonary intravascular coagulopathy is not unique to the MAS-like pattern of inflammation. Diffuse alveolar infection, activation of innate immune mechanisms, dysregulation of ACE2 protein expression, and marked adaptive antiviral immune responses could contribute to extensive pulmonary immunothrombosis without a clinically evident MAS (panel). Will this translate into differential effectiveness, if any, of immunosuppressive therapy between the MAS-like subgroup of patients and individuals without MAS? Ultimately, the tropism of COVID-19 for type II pneumocytes, along with evidence for extensive microvascular thrombosis during a global pandemic in patients without natural immunity, suggests an explanation for the increased cardiovascular mortality that has been recognised for some time in other settings of respiratory infection. We believe that this pulmonary intravascular coagulopathy, or pulmonary immunovascular coagulopathy, is the best explanation for the COVID-19 pneumonia risk factors for poor survival (eg, cardiovascular disease) in the present scenario, in which little evidence exists for systemic viraemia early in the COVID-19 disease course. 36 Contributors DM and CB developed the initial concepts for this Viewpoint. JSO and KS contributed to first draft writing. DM and CB wrote the final draft. DM, CB, and JSO did the literature review and critically revised the Viewpoint. KS made the figures. JSO and KS edited the Viewpoint. PE edited and approved the final draft. All authors have participated sufficiently in this work, take public responsibility for the content, and have made substantial contributions to this research. This manuscript has not been submitted to another journal and has not been published in whole, or in part, elsewhere previously.

DM has received honoraria and grant funding from Novartis and Sobi, and honoraria from Roche. All other authors declare no competing interests.

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease

Hemophagocytic lymphohistiocytosis: review of etiologies and management

COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning

Patient data, early SARS epidemic

Lung pathology of fatal severe acute respiratory syndrome

Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis

Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore

Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

Risk of myocardial infarction and stroke after acute infection or vaccination

Cardiac complications in patients with communityacquired pneumonia: incidence, timing, risk factors, and association with short-term mortality

Pulmonary pathology of severe acute respiratory syndrome in Toronto

Histopathologic and immunohistochemical features of fatal influenza virus infection in children during the 2003-2004 season

ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia

Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. bioRxiv 2020: published online

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury

Middle East Respiratory Syndrome

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

A novel coronavirus from patients with pneumonia in China

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

The clinical pathology of severe acute respiratory syndrome (SARS): a report from China

Pathology and pathogenesis of severe acute respiratory syndrome

Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19)

Vander Heide RS. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans

Association between cardiac injury and mortality in hospitalized patients infected with avian influenza A (H7N9) virus

Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care

Virological assessment of hospitalized patients with COVID-2019

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Fulminant myocarditis associated with pandemic H1N1 influenza A virus in children

Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS

Multiple organ infection and the pathogenesis of SARS

Molecular pathology in the lungs of severe acute respiratory syndrome patients

Expression of elevated levels of proinflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Myocarditis: current trends in diagnosis and treatment

Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells

Cardiovascular implications of fatal outcomes of patients with coronavirus disease

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Coagulation and sepsis

The stimulation of thrombosis by hypoxia

Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome

Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome

The role of bronchoalveolar hemostasis in the pathogenesis of acute lung injury

Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility

Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction

Hypoxia/ hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia

Thrombosis as an intravascular effector of innate immunity

Intravascular immunity: the host-pathogen encounter in blood vessels

Innate immunity to adenovirus: lessons from mice

Exacerbated innate host response to SARS-CoV in aged non-human primates

Circulating, interferon-producing plasmacytoid dendritic cells decline during human ageing

Influenza-induced production of interferon-alpha is defective in geriatric individuals

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Coagulopathy and antiphospholipid antibodies in patients with covid-19

Antiinflammatory therapy with canakinumab for atherosclerotic disease

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

The coagulation and immune systems are directly linked through the activation of interleukin-1α by thrombin

Thromboembolism with Janus kinase (JAK) inhibitor for rheumatoid arthritis: how real is the risk?

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI Features

Fatal H1N1-related acute necrotizing encephalopathy in an adult

Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between

Real estimates of mortality following COVID-19 infection

COVID-19 and African Americans

Effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2